Sakti Medical Systems

Website http://www.sakti.co

Founded 2017

Overview

Drug abuse and addiction - for both prescription painkillers and illicit substances - is a major public healthcare crisis. Sakti combines traditional diagnostic testing with proprietary software, algorithms and databases to provide physicians treating these patients with better clinical decision support, and provide payors/insurers with an outcome driven program providing better value for money spent on addiction prevention and treatment.

Video Pitch

Management Team

Managing Director (CEO)

Paul Pyzowski

Paul was co-founder and/or executive management at four prior companies in diagnostics, devices, and software. These include Ansoft, a software company sold for $750M; NetBio, a closely held MIT-Whitehead spinoff that has launched the first field-portable DNA sequencer; and Aleva Neurotherapeutics, a medical device company that has raised $15M in venture capital and is entering clinical trials of a device to treat Parkinson’s Disease.

Medical Director

Hari Sundram

Hari Sundram MD is both a practicing physician and a co-founder of several medical technology companies, two of which were both sold for greater than 10X return to major medical device strategics. He has eight awarded patents, all licensed to startups or major corporations in the drug and device industry. Dr. Sundram completed his Pain Medicine Fellowship at MGH and his Anesthesiology Residency at the University of Pennsylvania.

Co-Founder

Gary Robelen

Gary Robelen MD is the Chair of the Department of Anesthesiology & Pain Medicine at St. Elizabeth’s Medical Center, and also Associate Clinical Professor of Anesthesiology, Tufts University School of Medicine. He is also President of CAP Anesthesia, a private physician group under a long term contract to provide pain and anesthesia services to several Steward Healthcare hospitals.

Co-Founder

Eugene Chiu

Eugene is an entrepreneur and executive experienced in both software and clinical diagnostics. He was previously co-founder/VP Commercial Operations for Predictive Biosciences, a clinical lab that also is developing its own proprietary cancer tests. He has an MBA from Harvard Business School and had previously consulted for McKinsey.